Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
OMO-103 in Phase 1b clinical trial Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has...